Clinical Trials Logo

Filter by:
NCT ID: NCT05304741 Recruiting - Colorectal Cancer Clinical Trials

The Culture of Advanced/Recurrent/Metastatic Colorectal Cancer Organoids and Drug Screening

Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

The study aims to establish an organoids platform and apply them to screen drugs for advanced/recurrent/metastatic colorectal cancer patients.

NCT ID: NCT05304559 Recruiting - Hip Fractures Clinical Trials

Effects of S-ketamine and Continuous Iliac Fascia Space Block on Perioperative Neurological Cognitive Impairment and Postoperative Rehabilitation in Elderly Patients With Hip Fracture

Start date: March 26, 2022
Phase: N/A
Study type: Interventional

Elderly patients with hip fracture are older and have a high incidence of perioperative complications. the postoperative recovery of elderly patients with hip fracture is affected by hemodynamic instability and pain caused by fracture. S-ketamine is the S-isomer of ketamine. Compared with traditional ketamine, S-ketamine has stronger analgesic effect and fewer adverse reactions of nervous system. The parasympathetic effect of S-ketamine can antagonize the circulatory inhibition of propofol and make the hemodynamics more stable in elderly patients with hip fracture.Iliac fascial space block (fasciailiacacompartmentblock,FICB) mainly depends on local anesthetics spreading to the femoral nerve, lateral femoral cutaneous nerve and obturator nerve in the iliofascial space to achieve analgesia in its dominant area. Ultrasound-guided iliac fascial space block can effectively reduce the amount of anesthetics and has shorter puncture time and fewer complications. It can more effectively reduce the perioperative pain of elderly patients with hip fracture.

NCT ID: NCT05304468 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Start date: March 29, 2022
Phase: Phase 3
Study type: Interventional

To study the 2-year PFS (progression-free survival) of patients with stage II-III nasopharyngeal carcinoma treated with induction chemotherapy followed by two different doses of intensity modulated radiation therapy plus concurrent cisplatin chemotherapy

NCT ID: NCT05303844 Recruiting - Clinical trials for Refractory Malignant Ascites

Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites

Start date: April 2, 2022
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab for patients with refractory malignant ascites.

NCT ID: NCT05303285 Recruiting - Clinical trials for Ankylosing Spondylitis (AS)

A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis

Start date: June 14, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of secukinumab 300mg in Chinese adults participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).

NCT ID: NCT05303272 Recruiting - Pemphigus Vulgaris Clinical Trials

A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.Abatacept is a biologic drug that belongs to the class of T-cell co-stimulation modulators and is used for the treatment of autoimmune diseases.

NCT ID: NCT05303259 Recruiting - Brain Injuries Clinical Trials

Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury

BRAIN
Start date: November 1, 2021
Phase: Phase 2
Study type: Interventional

To investigate the effect of Bevacizumab on asymptomatic radiotherapy-induced brain injury patients with head and neck cancer.

NCT ID: NCT05303090 Recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Start date: March 31, 2022
Phase: Phase 1
Study type: Interventional

The objective of this study is to evaluate the safety/tolerability efficacy of oncolytic virotherapy combined with Tislelizumab plus lenvatinib for advanced pancreatic cancer patients who were relapsed or refractory to standard therapy

NCT ID: NCT05303038 Recruiting - Clinical trials for Metastatic Breast Cancer in the Liver

Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Castle06(BC)
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

This is a Phase II, open-label study evaluating the efficacy and safety of Cryoablation combined with Tirelizumab and Bevacizumab in liver metastatic triple-negative breast cancer patients failed by multiline therapy.

NCT ID: NCT05302843 Recruiting - Clinical trials for Metastasis, Neoplasm

A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors

Start date: March 22, 2021
Phase: Phase 1
Study type: Interventional

This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors